Emergent BioSolutions
Emergent BioSolutions Inc., a leading biopharmaceutical company headquartered in the United States, specialises in developing and manufacturing vaccines and therapeutics for public health threats. Founded in 1998, the company has achieved significant milestones, including the acquisition of key assets that bolster its position in the biodefence and infectious disease sectors. With a strong operational presence across North America and Europe, Emergent BioSolutions focuses on core products such as vaccines for anthrax and smallpox, as well as treatments for opioid overdose. What sets the company apart is its commitment to addressing urgent health needs through innovative solutions and strategic partnerships. Recognised for its expertise in biodefence, Emergent BioSolutions continues to play a pivotal role in enhancing global health security.
DitchCarbon Score
How does Emergent BioSolutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emergent BioSolutions's score of 43 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Emergent BioSolutions's reported carbon emissions
In 2024, Emergent BioSolutions reported total carbon emissions of approximately 12,800,000 kg CO2e for Scope 1 and about 14,812,000 kg CO2e for Scope 2, resulting in a combined total of around 27,357,000 kg CO2e for both scopes. This marks a decrease from 2023, where emissions were approximately 16,856,000 kg CO2e for Scope 1 and about 18,436,000 kg CO2e for Scope 2, leading to a total of around 35,292,000 kg CO2e. In 2022, the company recorded emissions of about 19,334,000 kg CO2e for Scope 1 and approximately 21,099,000 kg CO2e for Scope 2, culminating in a total of around 40,434,000 kg CO2e. Emergent BioSolutions has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The company does not appear to have cascaded emissions data from a parent organisation, and all reported figures are derived directly from Emergent BioSolutions Inc. Overall, while the company has shown a reduction in emissions from 2022 to 2024, there are no formalised targets or pledges to further enhance their climate strategy at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 19,334,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 21,099,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Emergent BioSolutions is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
